An extension of AC-055-310, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and Spanish versions of the PAH-SYMPACT
Phase of Trial: Phase III
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms ORCHESTRA Ext.
- Sponsors Actelion Pharmaceuticals
- 25 Sep 2018 Status changed from active, no longer recruiting to completed.
- 16 Aug 2018 Planned End Date changed from 30 Jun 2018 to 19 Sep 2018.
- 16 Aug 2018 Planned primary completion date changed from 30 Jun 2018 to 19 Sep 2018.